A respected RNAi therapeutics company.

These email address details are important because we believe TTR suppression gets the potential of halting or even reversing disease pathology in ATTR sufferers, said Teresa Coelho, M.D., Director, Unidade Clinica de Paramiloidose. I support the continuing advancement of this innovative medicine, and look forward to results out of this new study, along with additional clinical research. The Phase I trial of ALN-TTR02 has been conducted in the U.K. As a randomized, single-blind, placebo-controlled, single-ascending dose study, enrolling approximately 32 healthy volunteer subjects. The principal objective of the study is to judge the security and tolerability of an individual dose of ALN-TTR02, with subjects being enrolled into five sequential cohorts of raising doses ranging from 0.01 to 0.50 mg/kg.The researchers said they were amazed to find such high degrees of need at a major center which has resource specialists to greatly help patients’ families facing financial problems. What it says is usually that even at a well-resourced, large referral center, about a third of families are reporting food, housing or energy insecurity six months into treatment, study lead author Dr. Kira Bona, a pediatric oncologist at Dana-Farber/Boston Children’s, stated in a center news release. If anything, the quantities in our study are an underestimate of what may be seen at much less well-resourced institutions, that was surprising to us somewhat, Bona added. The findings were published Sept. 23 in the journal Pediatric Blood & Malignancy. Recent research has shown that young cancer individuals in low-income families are less inclined to take chemotherapy drugs as approved and also have lower survival rates, the study authors said.